Efficacy and Safety of Glucagon‐Like Peptide‐1 Receptor Agonists for Obesity Management in Adults With and Without Type 2 Diabetes: A Systematic Review
Jena Velji-Ibrahim, Dhruvil Radadiya, Kalpit Devani, Harsh K. Patel, Piyush Nathani, Cesare Hassan, Nicola Pugliese, C. Thompson, Prateek Sharma
Abstract
Objective: This systematic review aimed to assess the efficacy and safety of GLP-1 RAs in adults with obesity or overweight, by comparing different GLP-1 RAs, identifying the most effective agents, and evaluating adverse effects. Methods: ), with or without type 2 diabetes (T2DM). We excluded crossover trials, open-label studies, early-phase trials, and studies focusing on specific subpopulations. Results: A total of 22 RCTs involving 41,757 participants were included. Among adults with T2DM, the greatest weight reductions were observed with tirzepatide 15 mg (-9.5 kg at 40 weeks; 72% lost ≥ 5% of baseline weight) and semaglutide 2.4 mg (-9.6% body weight at 68 weeks; 69% lost ≥ 5%). In participants without T2DM, semaglutide 2.4 mg (-14.9% body weight at 68 weeks) and tirzepatide 15 mg (-20.9% at 72 weeks) produced the most substantial effects, while semaglutide 50 mg was also effective in nondiabetic patients. Liraglutide 3 mg showed modest efficacy. Across trials, GLP-1 RAs were consistently associated with a higher frequency of gastrointestinal adverse events compared to placebo, including nausea (14%-28% vs. 5%-10%), vomiting (6%-12% vs. 2%-4%), and diarrhea (8%-20% vs. 4%-7%). The risk of pancreatitis and serious adverse events remained comparable to placebo. Conclusions: GLP-1 RAs, especially semaglutide and tirzepatide, are effective for weight management. Liraglutide may remain a viable, cost-effective alternative.